NXI Therapeutics

NXI Therapeutics is a spin-off from the Biozentrum of the University of Basel, Switzerland, founded by Professor Jean Pieters and Chief Operating Officer Dr. med. Rajesh Jayachandran. The company focuses on the clinical application of T cell-mediated autoimmune diseases and is committed to creating future disruptive immunotherapies by modulating coronavirus 1 in immune cells. The uniqueness of the induced immunomodulation lies in its selectivity for autoimmune and alloimmune responses, while immune responses to infections and cancer remain unaffected.